Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cara Therapeutics, Inc.

https://www.caratherapeutics.com/

Latest From Cara Therapeutics, Inc.

Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug

The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.

Renal Deals

Keeping Track: US FDA Approves Korsuva, Skytrofa And Comirnaty, But Tecentriq Loses TNBC Indication

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

Cara Gets US Approval Of I.V. Korsuva, But Prospects Murky For Oral Version

The kappa opioid receptor agonist is not listed as a scheduled substance and labeling meets expectations. Cara and partner Vifor plan to launch the product in early 2022.

Approvals Business Strategies

Vifor Confident Of Clinching Two Deals Before Year-End

The Swiss group has posted a solid if unspectacular set of six-month results and is "working on a number of opportunities" that should close by the end of the year, according to its CFO.

Sales & Earnings Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register